Full text is available at the source.
Abstract
Survodutide improved markers of cardiometabolic health in people with obesity.
- Survodutide acts as a dual agonist for glucagon and GLP-1 receptors.
- Improvements were noted in various markers associated with cardiometabolic health.
- The cardiovascular safety of this new class of medication is still uncertain.
Simplified